Page last updated: 2024-12-07

indobufen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

indobufen: thromboxane A2 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107641
CHEMBL ID1765292
CHEBI ID135239
SCHEMBL ID140517
MeSH IDM0074020

Synonyms (72)

Synonym
AC-672
OPREA1_118499
benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-ethyl-
ENAMINE_001568
ibustrin
k-3920 ,
indobufen
1-oxo-2-(p-((alpha-ethyl)carboxymethyl)phenyl)isoindoline
indobufene [inn-french]
einecs 264-364-4
benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-
4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-benzeneacetic acid
k 3920
benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-alpha-ethyl-, (+-)-
indobufenum [inn-latin]
2-(4-(1-oxo-2-isoindolinyl)phenyl)butyric acid
(+-)-2-(p-(1-oxo-2-isoindolinyl)phenyl)butyric acid
butyric acid, 2-(p-(1-oxo-2-isoindolinyl)phenyl)-, (+-)-
indobufen [inn]
D07141
indobufen (inn)
63610-08-2
CHEBI:135239
HMS1398H06
(2s)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]butanoic acid
36690-96-7
2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]butanoic acid
CHEMBL1765292
k-2930 ,
AKOS015917718
6t9949g4lz ,
indobufene
unii-6t9949g4lz
(+-)-2-(4-(1-oxo-2-isoindolinyl)phenyl)buttersaeure
(+-)-2-(4-(1,3-dihydro-1-oxo-2-isoindolyl)buttersaeure
indobufenum
FT-0616451
1-oxo-2-(p-((.alpha.-ethyl)carboxymethyl)phenyl)isoindoline
2-(4-(1-carboxypropyl)phenyl)-1-isoindolinone
4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-ethylbenzeneacetic acid
benzeneacetic acid, 4-(1,3-dihydro-1-oxo-2h-isoindol-2-yl)-.alpha.-ethyl-, (+/-)-
(+/-)-2-(p-(1-oxo-2-isoindolinyl)phenyl)butyric acid
indobufen [mart.]
indobufen [mi]
indobufen [who-dd]
S5019
SCHEMBL140517
cas-63610-08-2
dtxsid7057789 ,
tox21_113871
dtxcid8031578
NCGC00253758-01
KS-5220
J-521529
(+/-)-2-[p-(1-oxo-2-isoindolinyl)phenyl]butyric acid
DB12545
2-(4-(1-oxoisoindolin-2-yl)phenyl)butanoic acid
BCP04485
Q3798322
mfcd00572250
HY-18763
AMY33419
CS-0014291
CCG-267421
D70894
4-(1,3-dihydro-1-oxo-(2h)-isoindol-2-yl)-alpha-ethylbenzeneacetic acid
A851741
SB66092
(+/-)-indobufen
Z56804486
EN300-18215281
2-[4-(1-oxo-2,3-dihydro-1h-isoindol-2-yl)phenyl]butanoic acid

Research Excerpts

Overview

Indobufen is an antiaggregatory drug which first of all inhibits platelet aggregation by interfering with cyclooxygenase enzymes in platelets. Studies were not sufficient on its anticoagulant effects.

ExcerptReferenceRelevance
"Indobufen is a new generation of anti-platelet aggregation drug, but studies were not sufficient on its anticoagulant effects. "( Anticoagulant Activities of Indobufen, an Antiplatelet Drug.
Chen, S; Hou, K; Li, Y; Liu, J; Wang, Y; Xia, N; Xu, D, 2018
)
2.22
"Indobufen is an antiaggregatory drug which first of all inhibits platelet aggregation by interfering with cyclooxygenase enzymes in platelets. "( Lipid peroxidation products and changes in phospholipid composition induced by indobufen in diabetic platelets.
Dmoszyńska, A; Ledwozyw, A; Walter-Croneck, A, 1995
)
1.96
"Indobufen is a possible alternative antiplatelet agent that may be better tolerated."( Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency one year after coronary artery bypass grafting.
Beton, D; Campbell, C; Critchley, A; Lawson, RA; Nair, U; Rajah, SM; Rees, M; Saunders, N; Walker, D; Williams, G, 1994
)
1.28
"Indobufen is a reversible inhibitor of platelet prostaglandin G/H-synthase. "( Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.
Catalano, I; Cosentino, F; Custro, N; Davì, G; Ganci, A; Giammarresi, C; Notarbartolo, A; Patrono, C, 1993
)
1.97
"Indobufen is an inhibitor of platelet aggregation which acts by reversibly inhibiting the platelet cyclo-oxygenase enzyme. "( Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease.
Buckley, MM; Fitton, A; Wiseman, LR, 1992
)
3.17
"Indobufen is an antiplatelet drug able to inhibit thromboxane production and cyclooxygenase-dependent platelet aggregation by a reversible inhibition of cyclooxygenase. "( The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man.
Bernini, W; De Caterina, R; Efthymiopoulos, C; Giannessi, D; Lazzerini, G; Sicari, R; Strolin-Benedetti, M; Yan, A, 1992
)
2.03

Effects

ExcerptReferenceRelevance
"Indobufen has been shown to be as effective as aspirin plus dipyridamole in preventing the reocclusion of coronary and femoro-popliteal artery bypass grafts and has been shown to significantly reduce platelet deposition on haemodialysis membranes."( Indobufen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in cerebral, peripheral and coronary vascular disease.
Buckley, MM; Fitton, A; Wiseman, LR, 1992
)
2.45

Actions

ExcerptReferenceRelevance
"Indobufen was found to cause transitory changes of platelet function."( [Clinical-experimental studies on the inhibition of thrombocyte function with acetylsalicylic acid and with indobufen].
Vinazzer, H, 1979
)
1.19

Treatment

Indobufen treatment prevented thrombus formation completely in 14 of 15 rats (p less than 0.02) In dogs a similar mobilization of 111In-labelled platelets was evident only after the second adrenaline injection.

ExcerptReferenceRelevance
"In indobufen-treated dogs a similar mobilization of 111In-labelled platelets with an increase in circulating platelet numbers was evident only after the second adrenaline injection."( Different patterns of inhibition of adrenaline-induced platelet aggregation and kinetics in vivo by acetylsalicylic acid and indobufen.
Amaral, I; Fortunato, JS; Monteiro, MC; Pinheiro, MJ; Rodrigues, MA,
)
0.85
"Indobufen treatment prevented thrombus formation completely in 14 of 15 rats (p less than 0.02)."( Antithrombotic effect of indobufen in an experimental model of arterio-arterial microanastomosis in the rat.
Carrieri, P; Cerillo, A; Donzelli, R; Orefice, G; Tayana, G; Volpentesta, G, 1987
)
1.3
"Pre-treatment with indobufen clearly inhibited beta-TG and PF 4 output."( Beta-thromboglobulin and platelet factor 4 plasma levels during haemodialysis: effect of indobufen.
Buccianti, G; Colombi, M; Cristoforetti, G; Miradoli, R; Pogliani, EM; Valenti, G, 1982
)
0.8
"Treatment with indobufen after carotid surgery seems to be effective as far it was restricted to an homogeneous group of patients presenting symptomatic extracranial carotid disease."( Antiplatelet treatment after carotid endarterectomy: a pilot study.
Bono, G; Gaetani, P; Lavezzari, M; Milanesi, G; Rodríguez y Baena, R,
)
0.47

Pharmacokinetics

The plasma half-life of the drug was 7--8 h and more than 70% of the administered dose was recovered within 48 h in urine. Calculated parameters confirmed usefulness of the method in human pharmacokinetic studies on indobufen enantiomers.

ExcerptReferenceRelevance
" The plasma half-life of the drug was 7--8 h and more than 70% of the administered dose was recovered within 48 h in urine, as unchanged drug and as the glucuronide of indobufen."( Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man.
Corvi, G; Fuccella, LM; Moro, E; Pogliani, E; Tamassia, V; Tosolini, G, 1979
)
0.69
" No significant differences were detected between single dose and steady-state as regards pharmacokinetic parameters of the drug which, at steady-state, were (mean +/- SD, n = 16): Cmax = 32."( Effect of age on the pharmacokinetics of indobufen.
Borghetti, A; Castiglioni, A; Cavatorta, A; Garini, G; Montanari, M; Savazzi, GM, 1986
)
0.54
" Calculated parameters confirmed usefulness of the method in human pharmacokinetic studies on indobufen enantiomers."( Resolution of indobufen enantiomers by capillary zone electrophoresis. Pharmacokinetic studies of human serum.
Główka, FK; Karaźniewicz, M, 2004
)
0.9
"This study aimed to investigate the pharmacodynamic effects of indobufen and low-dose aspirin in patients with coronary atherosclerosis."( Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
Abdus, S; Bai, J; Eikelboom, JW; Gong, X; Gu, Q; Li, C; Lu, Y; Mei, L; Shi, L; Tan, C; Ullah, I; Wang, G; Yang, M; Ye, Z, 2021
)
1.16

Dosage Studied

Indobufen was first given as a single 200 mg dose and then for a 5 day period in a dosage of 200 mg twice daily, to six healthy volunteers. Urinary 8-epi-PGF2 alpha was unchanged after 2-week dosing with aspirin and indibufen despite complete suppression of TX metabolite excretion.

ExcerptRelevanceReference
" The method was validated for the determination of the optical purity of (S)-(+)-indobufen as a quality control method for finished dosage forms."( High-performance liquid chromatographic method for direct resolution of the indobufen enantiomeric components.
Farina, M; Perrone, G, 1990
)
0.73
"Controlled release high dosage forms of a typical drug such as Indobufen were prepared as multiple-unit doses by employing extrusion-spheronization processing and subsequently film coating operations."( Oral controlled release optimization of pellets prepared by extrusion-spheronization processing.
Bianchini, R; Vecchio, C, 1989
)
0.52
" Indobufen was first given as a single 200 mg dose and then for a 5 day period in a dosage of 200 mg twice daily, to six healthy volunteers."( Indobufen interacts with the sulphonylurea, glipizide, but not with the beta-adrenergic receptor antagonists, propranolol and atenolol.
Elvander-Ståhl, E; Melander, A; Wåhlin-Boll, E, 1984
)
2.62
" Regardless of the dosage used, indobufen was shown to induce a prompt normalization of the enhanced platelet aggregation of these patients."( Inhibition of spontaneous platelet aggregation and adhesion by indobufen (K 3920). A randomized, double-blind crossover study on platelet, coagulation and fibrinolysis function tests.
Ballatori, E; Berrettini, M; Iadevaia, V; Nenci, GG; Parise, P, 1982
)
0.79
" Urinary 8-epi-PGF2 alpha was unchanged after 2-week dosing with aspirin and indobufen despite complete suppression of TX metabolite excretion."( In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Alessandrini, P; Bon, GB; Bucciarelli, T; Ciabattoni, G; Cipollone, F; Costantini, F; Davi, G; Mezzetti, A; Minotti, G; Patrono, C, 1997
)
0.53
" The morphological and functional results clearly demonstrated the tangential spray rotary system as a promising one-step technique for the preparation of indobufen prolonged-release multiple-unit dosage forms."( Rotary tangential spray technique for aqueous film coating of indobufen pellets.
Fabiani, F; Gazzaniga, A; Sangalli, ME; Vecchio, C; Zema, L, 1998
)
0.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoindoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency9.77170.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency4.97330.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency1.69300.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency1.69300.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency10.89830.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency5.38800.000221.22318,912.5098AID1259243; AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency8.08300.001022.650876.6163AID1224838; AID1224839; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency3.44630.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency2.39140.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency9.67210.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency4.73080.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.71820.000229.305416,493.5996AID1259244; AID1259248
cytochrome P450 2D6Homo sapiens (human)Potency27.54040.00108.379861.1304AID1645840
histone deacetylase 9 isoform 3Homo sapiens (human)Potency3.28260.037617.082361.1927AID1259364; AID1259388
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency1.67850.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency37.35650.00339.158239.8107AID1347407
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency1.67850.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (30)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (139)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (34.53)18.7374
1990's58 (41.73)18.2507
2000's11 (7.91)29.6817
2010's9 (6.47)24.3611
2020's13 (9.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.08 (24.57)
Research Supply Index5.37 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index59.54 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials58 (37.42%)5.53%
Reviews7 (4.52%)6.00%
Case Studies1 (0.65%)4.05%
Observational0 (0.00%)0.25%
Other89 (57.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Pharmacokinetic and Pharmacodynamic Characteristics of Indobufen, an Anticoagulant Agent [NCT01232023]Phase 112 participants (Anticipated)Interventional2010-01-31Recruiting
A Comparative Study on Antiplatelet Efficacy of Indobufen and Aspirin in Patients With Coronary Atherosclerosis [NCT05105750]Phase 460 participants (Anticipated)Interventional2021-10-15Recruiting
INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE [NCT03871517]Phase 45,438 participants (Actual)Interventional2019-06-03Completed
Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Stable Coronary Heart Disease. A Prospective, Randomized and Controlled,Single Blind, Single-center, Opening Study [NCT04308551]594 participants (Anticipated)Interventional2021-12-30Not yet recruiting
II Italian Study on Atrial Fibrillation (S.I.F.A. II): Prevention of Thromboembolic Events in Patients With Non Valvular Atrial Fibrillation. [NCT00244426]Phase 31,372 participants (Actual)Interventional2000-12-31Completed
Effect of Indobufen Versus Aspirin on Gastric Acid Secretion and Gastroesophageal Reflux in Patients With Coronary Heart Disease and Gastroesophageal Reflux Disease Undergoing Dual Antiplatelet Therapy: a Prospective, Randomized, Double-blind, Double-dumm [NCT04129008]Phase 488 participants (Anticipated)Interventional2019-10-17Not yet recruiting
the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy [NCT03230851]Phase 4210 participants (Anticipated)Interventional2017-08-20Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]